Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects who have advanced, recurrent or refractory FRα overexpressing tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects who have advanced, recurrent or refractory FRα overexpressing tumors
NCT #
NCT05001282
Condition(s)
Cholangiocarcinoma, Colorectal, Endometrial, Gastric, Gastric/GEJ (Gastroesophageal Junction)/Esophageal, Non-Small Cell Lung, Ovarian, triple negative Breast
Molecular Target(s)
DNA topoisomerase I
Drug Classification(s)
C'Dot drug conjugate
Agents(s)
ELU001
Phase(s)
I/II
Mechanism of Action
ELU001 is a 7 nm size silica particle that has attached folate molecules to bind to cells with folate receptor in order to deliver the attached cytotoxic payload molecules..
Purpose
- How much of the study can be given with an acceptable level of side effects
- The effects of the study (good and bad)
- How much of the study is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from ELU001
- Part 1 Documented diagnosis of ovarian cancer, endometrial cancer, colorectal cancer, gastric cancer, gastroesophageal junction cancer, triple negative breast cancer, non-small cell lung cancer, or cholangiocarcinoma
- Part 2 Ovarian Cancer or Endometrial Cancer
- No other meaningful life-prolonging therapy option available
- Must provide archival tumor tissue or a newly obtained tumor biopsy specimen prior to the first dose of ELU001 for folate receptor alpha (FRα) expression analysis. Previous FRα expression test results may be used in certain circumstances
- Adequate organ function
- Measurable disease, or in the absence of measurable disease, non-measurable disease as per Response evaluation criteria in solid tumors (RECIST) v1.1
- Part 1: Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2; Part 2: ECOG performance status of 0 or 1.
- Recovered from previous surgeries
- Agree to highly effective contraception, not to get pregnant, or for men, not father a child during study participation
- Active or ongoing eye disorders
- Taken any treatments that use the protein folate receptor alpha or FRα to work
- Taken any other experimental treatments
- History of significant cardiac issues or other cancers within 3 years.
- Significant anemia, significant neutropenia, or significant thrombocytopenia (e.g., not enough platelets in your blood – platelets held stop bleeding in your body)
- Detectable viral load for HIV (human immunodeficiency virus), hepatitis B or C.
- If you are pregnant.
- Part 1: Cannot have active autoimmune diseases such as rheumatoid arthritis, SLE (systemic lupus erythematosus), ulcerative colitis, Crohn’s Disease, MS (multiple sclerosis), ankylosing spondylitis, thyroiditis that require treatments that suppress your immune system.
- Part 1: if your cancer has spread to your brain.
- Part 2: You can have cancer that has spread to your brain but there are exceptions. The cancer in your brain cannot be causing any symptoms, it cannot be larger than 3 cm, there can be no evidence on a scan that shows your brain tissue has shifted from its expected position inside the skull (called “herniation”) or be bleeding in the skull or brain itself (called “hemorrhage”)
FRα Expressing Tumors potentially sensitive to topoisomerase 1 inhibitors, any treatments that use the protein folate receptor alpha or FRα to work
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site
MCLA-128-CL01
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
n/a
NRG1 fusion
Non-Small Cell Lung, Pancreatic
MCD
MCLA-129-CL01
MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody
n/a
EGFR, MET
esophageal Squamous Cell Carcinoma, Gastric/GEJ (Gastroesophageal Junction)/Esophageal, head and neck squamous cell carcinoma, Non-Small Cell Lung
MCD
23-27
AB801 is an AXL inhibitor
Monoclonal Antibody (Immunotherapy, Small Molecule (Targeted), targeted
STK11
Non-Small Cell Lung
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.